SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414The suspension of trading in the securities of Cogstate Ltd will be lifted immediately following the release by CGS of an announcement regarding a response to an ASX Price Query. | 24/02/2023 |
The company issues a response to ASX Price Query. | 24/02/2023 |
Cogstate will release its half year report for the period ending 31 December 2022 (Appendix 4D) to ASX on 28 February 2023. For context, at 01 July 2022, Cogstate had contracted future revenue of $139.1m, of which it expected $29.7m to be recognized as revenue in FY23. Cogstate now expects approximately $5m of that FY23 contracted revenue to be recognized in FY24 ($3.3m from 1H23 and the remainder expected to impact 2H23). The company also noted more confidence in respect of Clinical Trials sales contracts that were expected to positively impact revenue and profitability in 2H23. Current expectations are that some of the larger value contracts are now expected to execute late in 2H23 and therefore will contribute less revenue and profit in FY23 than previously expected, with a larger revenue contribution in FY24, assuming execution. Cogstate advises it expects to report breakeven profit before tax for 1H23. Cogstate executed $27.9m of Clinical Trials sales contracts during 1H23, consistent with the result for the most recent half year of 2H22, taking contracted future revenue at 31 December 2022 to $146.7m (up from $139m at 30 June 2022). The Company provides the following updated guidance in respect of the full year ended 30 June 2023: 2H23 revenue expected to increase over 1H23, but FY23 revenue expected to be approximately 6-9% below FY22; EBITDA is expected to be in the range of 12-15% of revenue (4/Nov/22 guidance of 27-29%); EBIT is expected to be in the range of 6-8% of revenue (4/Nov/22 guidance of 20-24%); and Cash balance as at 31 December 2022 of $29m; expect positive operating cash flow for 2H23. | 24/02/2023 |
The securities of Cogstate Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of CGS, pending the release of an announcement regarding a response to an ASX Price Query. | 23/02/2023 |
listed entity carried for record purposes only | 01/07/2004 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 29/08/2025 | Bradley O'Connor | 50,327 | $1.738 | $87,485.00 |
| 23/08/2024 | Martyn Myer | 100,000 | $1.081 | $108,051.00 |
| 16/05/2023 | Richard Mohs | 12,000 | $1.150 | $13,800.00 |
| 07/03/2023 | Martyn Myer | 50,000 | $1.535 | $76,750.00 |
| 02/03/2023 | Bradley O'Connor | 65,000 | $1.544 | $100,374.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Martyn Myer | Chairman | 01/10/1999 |
| Bradley O'Connor | CEO | 12/05/2004 |
| Darren Watson | CFO | 01/02/2021 |
| Ingrid Player | Independent Director | 29/08/2019 |
| Kim Wenn | Independent Director | 30/11/2020 |
| Richard Mohs | Non Exec Director | 20/01/2017 |
| David Franks | Company Secretary | |
| Kristi Geddes | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
